

# Jane Sinclair

## Personal Details

**Address** Brisbane, QLD, 4051, Australia  
**Phone** 0449 119 784  
**E-mail** [jane.sinclair@uqconnect.edu.au](mailto:jane.sinclair@uqconnect.edu.au)  
**Nationality** Australian  
**Language** English  
**ORCID ID** <https://orcid.org/0000-0002-9178-3869>



## Research Publications and Conference Presentations

---

**Sinclair, J.E.**, Vedelago, C., Ryan, F.J., Carney, M., Redd, M., Lynn, M.A., et al. (2024). Cardiovascular symptoms of PASC are associated with trace-level cytokines that affect the function of human pluripotent stem cell derived cardiomyocytes.

**Under review:** Nature Microbiology

**Sinclair, J.E.**, Mayfield, H.J., Brown, S.J., Waller, M., Williams, O., Litt, J.C.B., Short, K.R., Lau, C.L. (2024). A Bayesian network model for estimating risk of long COVID.

**Presented:** 7<sup>th</sup> Southern Cross Travel & Tropical Medicine Conference 2023; 9<sup>th</sup> ESWI Influenza Conference 2023; Bayesian Network Modelling Association (BNMA) Conference 2023

Shukla, T., **Sinclair, J.E.**, Mayfield, H.J., Litt, J.C.B., Short, K.R., Lau, C.L., et al. (2024). A Bayesian network analysis of the risks vs benefits of Pfizer COVID-19 vaccine in children. **Under submission.**

Steele, L.E., Wu, M., Sinclair, J.E., Ignacio, K., Macaulane, K.L., McCallum, G., et al. (2024). Prior measles and the severity of 1918 influenza: a case-control study. **Under submission.**

Scott, J., Mayfield, H.J., **Sinclair, J.E.**, Martin, B.M., Howlett, M., Muttucumar, R., et al. (2024). Field laboratory comparison of STANDARD Q Filariasis Antigen Test (QFAT) with Bioline Filariasis Test Strip (FTS) for the detection of lymphatic filariasis in Samoa, 2023. *PLOS Neglected Tropical Diseases*.

Speck, P., Mackenzie, J., Bull, R.A., Slobedman, B., Drummer, H., Fraser, J., ..., **Sinclair, J.E.**, et al. (2023). Statement in support of: "Virology under the microscope – a call for rational discourse". *Journal of Virology, mBio, mSphere*. doi: 10.1128/jvi.00451-23, 10.1128/mbio.00815-23, 10.1128/msphere.00165-23.

**Sinclair, J.E.**, Mayfield, H.J., Short, K.R., Brown, S.J., Puranik, R., Mengersen, K., Litt, J.C.B., Lau, C.L. (2022). Quantifying the risks versus benefits of the Pfizer COVID-19 vaccine in Australia: a Bayesian network analysis. *medRxiv*. doi: 10.1101/2022.02.07.22270637.

**Presented:** 9<sup>th</sup> Australasian Vaccines & Immunotherapeutics Development Meeting 2022

**Sinclair, J.E.**, Smith, C., Jacobson, K., Gras, S., Sato, K., Kulasinghe, A., Short, K.R. (2022). Chronic complications of influenza and COVID-19.

**Presented:** Immunisation Coalition Annual Scientific Meeting 2022

**Sinclair, J.E.**, Tong, Z.W.M., Noye, E.C., Yih Chew, K., Trau, M., Wuethrich, A., Smith, C., Short, K.R. (2021). *IL-6, IL-8 and IFN- $\beta$  are elevated in individuals with long COVID*.

**Presented:** ISIRV-WHO Virtual Conference 2021; 14<sup>th</sup> Australian Influenza Symposium 2021; The University of Queensland SCMB Research Student Symposium 2021; 60<sup>th</sup> ASMR National Scientific Conference 2021; 8<sup>th</sup> ESWI Influenza Conference Virtual Edition 2021; 2nd Australasian COVID-19 Conference 2022.

**Sinclair, J.E.**, Bloxham, C.J., Chiu, H., Chew, K.Y., Russell, J., Yoshikawa, Y., et al. Type I diabetes mellitus increases the cardiovascular complications of influenza virus infection. (2021). *Frontiers in Cellular and Infection Microbiology*. doi: 10.3389/fcimb.2021.714440.

**Presented:** 7<sup>th</sup> European Scientific Working Group on Influenza (ESWI) Conference; The Australian Virology Society (AVS) Virtual Symposium; The University of Queensland SCMB Research Student Symposium 2020.

**Sinclair, J.E.**, Zhu, Y., Xu, G., Ma, W., Shi, H., Ma, K.-L., et al. (2021). A meta-analysis on the role of pre-existing chronic disease in the cardiac complications of SARS-CoV-2 infection. *iScience*. doi: 10.1016/j.isci.2021.102264.

Wuethrich, A., **Sinclair, J.E.**, Henders, A.K., Li, J., Chew, K.Y., Vedelago, C., et al. (2023). Low-level inflammatory cytokines can be detected by nanotechnology in individuals with long COVID up to 20 months after SARS-CoV-2 infection. *Under consideration at Nature Microbiology*.

**Presented:** 11<sup>th</sup> Australasian Virology Society Meeting 2022.

Sato, K., **Sinclair, J.E.**, Sadeghirad, H., Fraser, J.F., Short, K.R., Kulasinghe, A. (2021). Cardiovascular disease in SARS-CoV-2 infection. *Clinical and Translational Immunology*. doi: 10.1002/cti2.1343.

Lau, C.L., Mayfield, H.J., **Sinclair, J.E.**, Brown, S.J., Waller, M., Enjeti, A.K., et al. (2021). Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework. *Vaccine*. doi: 10.1016/j.vaccine.2021.10.079.

Mayfield, H.J., Lau, C.L., **Sinclair, J.E.**, Brown, S.J., Baird, A., Litt, J., et al. (2021). Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine. *medRxiv*. doi: 10.1101/2021.10.28.21265588.

**Presented:** 13<sup>th</sup> Annual Australasian Bayesian Network Modelling Society Conference 2021; AI4PAN at Women's College Extended Lunch Working Group Meeting Day, 8 December 2021; 24<sup>th</sup> International Congress on Modelling and Simulation 2021.

Zhu, Y., Bloxham, C.J., Hulme, K.D., **Sinclair, J.E.**, Tong, Z.W.M., Steele, L.E., et al. (2020). A meta-analysis on the role of children in SARS-CoV-2 in household transmission clusters. *Clinical Infectious Diseases*. doi: 10.1093/cid/ciaa1825.

Kulasinghe, A., Liu, N., Tan, C.W., Monkman, J., **Sinclair, J.E.**, Bhuva, D.D., et al. (2022). Transcriptomic profiling of cardiac tissues from SARS-CoV-2 patients identifies DNA damage. *medRxiv*. doi: 10.1101/2022.03.24.22272732.

Tong, Z.W.M., Karawita, A.C., Kern, C., Zhou, H., **Sinclair, J.E.**, Yan, L., et al. (2021). Primary chicken and duck endothelial cells display a differential response to infection with highly pathogenic avian influenza virus. *Genes*. doi: 10.3390/genes12060901.

Zhou, P., Chen, J., Zheng, T., Yunis, J., Makota, V., Alexandre, Y.O., ..., **Sinclair, J.E.**, et al. (2021). Low-dose IL-2 therapy invigorates CD8<sup>+</sup> T cells for viral control in systemic lupus erythematosus with a potential risk of deteriorating immunopathology. *PLOS Pathogens*. doi: 10.1371/journal.ppat.1009858.